SPECIAL NOTICE
35 -- MiSEQ Service Contract and Upgrade
- Notice Date
- 5/10/2022 6:02:00 AM
- Notice Type
- Special Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- FDA OFFICE OF ACQ GRANT SVCS Beltsville MD 20705 USA
- ZIP Code
- 20705
- Solicitation Number
- FDA-22-1254841
- Response Due
- 5/20/2022 10:00:00 AM
- Point of Contact
- Julia Savage
- E-Mail Address
-
julia.savage@fda.hhs.gov
(julia.savage@fda.hhs.gov)
- Description
- NOTICE OF INTENT TO AWARD SOLE SOURCE Project Title: MiSEQ Service Contract and Upgrade Announcement No: FDA-22-1254841 The Government hereby submits a notice of intent to award a sole source contract to Illumina for a diagnostic check and system upgrades for the MISEQ Whole Genome Sequencer for six (6) FDA laboratories. The instrument and associated technology is proprietary to Illumina, such that all updates and repairs and maintenance must be performed by representatives of the vendor (Illumina) only. This sole source contracting action a notice pursuant to FAR 5.203(a) for the requirement based on the application of FAR 6.302-1.� This hereby constitutes a synopsis of this requirement. Responses to this notice must demonstrate clear and convincing evidence that competition would be advantageous to the Government, would not be cost or time prohibitive, and would not hinder the mission objective of the FDA. The determination not to compete this proposed contract action solely within the discretion of the Government.� Information received will normally be considered for the purposes of determining whether to conduct a competitive procurement.� The Government will not be responsible for any costs incurred by responding to this notice. This is NOT a request for quotes or proposals. Questions or comments to this Notice of Intent should be directed to Contract Specialist, Judy Savage, at Julia.Savage@fda.hhs.gov (via email only) and within 10 days of the notice of intent posting date. Please be advised no phone calls/voice mail messages regarding questions will be accepted and nor will they receive a response).� Please indicate in the subject line of your email: Notice of Intent Questions Submission � FDA-22-1254841
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/17f54857d54a459892af314b01ff2148/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN06322163-F 20220512/220510230051 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |